Pancreatic Cancer Research

ResearcherThe Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research InstituteActive in the last 2 years

Anne M. Noonan

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8083-8492; OpenAlex author ID A5009849305. Sources: ClinicalTrials.gov.

Their work

Papers
20
Trials
1 (principal investigator on 1)
Grants
0
Labs led
0
Collaborators
85
Papers, trials and grants by year

2010: 1 trial · 2011: none · 2012: none · 2013: none · 2014: none · 2015: 1 paper · 2016: 2 papers · 2017: 1 paper · 2018: none · 2019: 2 papers · 2020: 2 papers · 2021: 1 paper · 2022: 2 papers · 2023: none · 2024: 4 papers · 2025: 2 papers · 2026: 3 papers

Papers 20

  1. Simultaneous resection of pancreatic cancer and liver metastases following total neoadjuvant therapy: A case series and analysis of the National Cancer Databas… Co-author DOI 10.14701/ahbps.25-209↗
  2. Inferring Clinically Relevant Molecular Subtypes of Pancreatic Cancer from Routine Histopathology Using Deep Learning Co-author DOI 10.21203/rs.3.rs-8545050/v1↗
  3. Inferring Clinically Relevant Molecular Subtypes of Pancreatic Cancer from Routine Histopathology Using Deep Learning Co-author DOI 10.64898/2026.01.06.26343539↗
  4. Hospital admission during neoadjuvant therapy for pancreatic ductal adenocarcinoma: prevalence, predictors, and prognosis. Co-author DOI 10.1016/j.hpb.2025.08.015↗
  5. Quality Score Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma: Trends, Racial Disparities, and Impact on Outcomes. Co-author DOI 10.6004/jnccn.2024.7089↗
  6. Relacorilant plus nab-paclitaxel for the treatment of metastatic pancreatic ductal adenocarcinoma: results from the open-label RELIANT study. Co-author DOI 10.1093/oncolo/oyae210↗
  7. A Phase Ib/II Randomized Clinical Trial of Oleclumab with or without Durvalumab plus Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-24-0499↗
  8. Serum MUC5AC Predicts Recurrence in Pancreatic Ductal Adenocarcinoma Patients on Neoadjuvant Chemotherapy Co-author DOI 10.20944/preprints202409.0945.v1↗
  9. Mature MUC5AC Expression in Resected Pancreatic Ductal Adenocarcinoma Predicts Treatment Response and Outcomes. Co-author DOI 10.3390/ijms25169041↗
  10. Multi-specialty physician perspectives on barriers and facilitators to the use of neoadjuvant therapy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.hpb.2021.10.010↗
  11. Altered Plasma Fatty Acid Abundance Is Associated with Cachexia in Treatment-Naïve Pancreatic Cancer. Co-author DOI 10.3390/cells11050910↗
  12. Development of a MicroRNA Signature Predictive of Recurrence and Survival in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers13205168↗
  13. Neoadjuvant-modified FOLFIRINOX vs nab-paclitaxel plus gemcitabine for borderline resectable or locally advanced pancreatic cancer patients who achieved surgic… Co-author DOI 10.1002/cam4.3075↗
  14. Pathologic complete response following neoadjuvant therapy for pancreatic ductal adenocarcinoma: defining the incidence, predictors, and outcomes. Co-author DOI 10.1016/j.hpb.2020.01.013↗
  15. Comparison of conventional versus liposomal irinotecan in combination with fluorouracil for advanced pancreatic cancer: a single-institution experience. Co-author DOI 10.1007/s12032-019-1309-6↗
  16. Circulating interleukin-6 is associated with disease progression, but not cachexia in pancreatic cancer. Co-author DOI 10.1016/j.pan.2018.11.002↗
  17. A modified regimen of biweekly gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer is both tolerable and effective: a retrospective an… Co-author DOI 10.1177/1758834016676011↗
  18. Randomized Phase 2 Trial of the Oncolytic Virus Pelareorep (Reolysin) in Upfront Treatment of Metastatic Pancreatic Adenocarcinoma. Co-author DOI 10.1038/mt.2016.66↗
  19. Systemic Immune Activity Predicts Overall Survival in Treatment-Naïve Patients with Metastatic Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-15-1732↗
  20. Immunological predictors of overall survival in treatment naïve metastatic pancreatic cancer patients Co-author DOI 10.1186/2051-1426-3-s2-p85↗

Trials 1

  1. Carboplatin and Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Metastatic Pancreatic Cancer Principal investigator NCT01280058↗

Closest collaborators

The 25 strongest of 85 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ashish Manne · 6 shared papers, 2024–2026 · strength 1.31
  2. Jordan M. Cloyd · 8 shared papers, 2020–2026 · strength 1.26
  3. Mary E. Dillhoff · 8 shared papers, 2019–2026 · strength 1.19
  4. Timothy Michael Pawlik · 6 shared papers, 2019–2026 · strength 1.15
  5. Aslam M. Ejaz · 5 shared papers, 2020–2026 · strength 0.83
  6. Upender Manne · 4 shared papers, 2024–2026 · strength 0.83
  7. Ashwini Kumar Esnakula · 4 shared papers, 2024–2026 · strength 0.83
  8. Shafia Rahman · 4 shared papers, 2024–2026 · strength 0.79
  9. Eric David Miller · 4 shared papers, 2020–2025 · strength 0.62
  10. Muhammad Khalid Khan Niazi · 2 shared papers, 2026 · strength 0.53
  11. Abdul Akbar · 2 shared papers, 2026 · strength 0.53
  12. Susan Tsai · 2 shared papers, 2026 · strength 0.53
  13. Vaibhav Sahai · 2 shared papers, 2026 · strength 0.53
  14. Laith I. Abushahin · 3 shared papers, 2020–2026 · strength 0.47
  15. Allan Tsung · 3 shared papers, 2020–2022 · strength 0.37
  16. Kenneth L Pitter · 2 shared papers, 2024–2025 · strength 0.37
  17. Terence Marques Williams · 3 shared papers, 2020–2021 · strength 0.33
  18. Diamantis I. Tsilimigras · 1 shared paper, 2025 · strength 0.33
  19. Christos K Fountzilas · 2 shared papers, 2024 · strength 0.32
  20. Sameek Roychowdhury · 2 shared papers, 2024 · strength 0.31
  21. Kannan Thanikachalam · 2 shared papers, 2024 · strength 0.31
  22. Wancai Yang · 2 shared papers, 2024 · strength 0.31
  23. Lianbo Yu · 2 shared papers, 2024 · strength 0.31
  24. Ankur Sheel · 2 shared papers, 2024 · strength 0.31
  25. Anup Kasi · 2 shared papers, 2024 · strength 0.31

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.